Formulations
Standard Strength: 5 mg BPC-157 + 5 mg TB-500 (10 mg total)
Advanced Strength: 10 mg BPC-157 + 10 mg TB-500 (20 mg total)
Oral Backbone: RECOVER™ — 500 mcg BPC-157 + 2 mg GHK-Cu + 500 mg carnosine staged-release capsule, 1 cap AM, 5 days on / 2 days off
1. Clinical Overview
BPC-157 (Body Protection Compound-157)
Cytoprotective gastric pentadecapeptide. Potent angiogenic, endothelial-protective, GI-healing, and tendon/ligament-restorative peptide.
TB-500 (Thymosin Beta-4 Fragment)
Synthetic Tβ4 fragment. Dominant in actin cytoskeleton regulation, cell migration, angiogenesis, and wound repair.
The Wolverine Blend creates a single injectable, stacked regenerative platform combining BPC-157’s GI/endothelial/tendon repair with TB-500’s actin-mediated cell migration and robust angiogenesis.
2. Mechanisms & Synergy
2.1 BPC-157 Mechanisms
Angiogenesis/microvascular repair, fibroblast activation/collagen I synthesis, GI mucosal healing/barrier integrity, neuroprotective/endothelial modulation (NO/eNOS pathways).
2.2 TB-500 Mechanisms
Actin sequestration/G-actin binding/cell migration (keratinocytes, fibroblasts, myocytes), VEGF-driven angiogenesis, anti-inflammatory/anti-fibrotic (TNF-α, IL-6, neutrophil infiltration), tissue remodeling/collagen organization.
2.3 Synergy Model
| Domain | BPC-157 | TB-500 | Synergistic Result |
|---|---|---|---|
| Angiogenesis | Organized microvascular | VEGF-driven vessels | Robust ordered re-perfusion |
| Actin/Migration | Fibroblast support | Direct G-actin | High-velocity tissue repopulation |
| Tendon/Ligament | Tendon-to-bone, collagen I | Collagen alignment, ↓adhesion | Stronger organized repair |
| GI/Endothelial | Strong | Weak–moderate | Systemic protection during loading |
| Inflammation | Anti-inflammatory/NO | Anti-inflammatory/anti-fibrotic | Lower chronic burden, better scars |
| Neurovascular | Neuroprotection, stability | Emerging neuroregenerative | Neuroinflammatory support |
3. Clinical Applications
3.1 Musculoskeletal
Tendon/ligament healing, muscle/myofascial repair, improved tensile strength/collagen alignment, reduced recovery times.
3.2 Wound Healing & Aesthetic
Accelerated dermal closure, enhanced keratinocyte/fibroblast migration, improved scar quality, synergy with GHK-Cu, PRP/PRF, energy-based procedures.
3.3 GI / Endothelial / Systemic
BPC-157 GI/endothelial protection for patients on NSAIDs or under orthopedic stress. TB-500 vascular remodeling and anti-fibrotic actions.
4. Product Specifications
Advanced Vial: 10 mg BPC-157 + 10 mg TB-500 = 20 mg total
Routes: Peri-tendinous/peri-ligamentous, SC/IM systemic, mesotherapy dermal grids
RECOVER™ Oral: 500 mcg BPC-157 + 2 mg GHK-Cu + 500 mg carnosine, 1 cap AM, 5/2 cycle
5. Reconstitution & Dosing
Standard Strength (5 mg + 5 mg = 10 mg)
| Option | Diluent | Concentration | Use |
|---|---|---|---|
| A — High | 2 mL BS | 5 mg/mL total (2.5/2.5) | Focal tendon/ligament |
| B — Moderate | 5 mL BS | 2 mg/mL total (1/1) | Mesotherapy, larger fields |
| C — Low | 10 mL BS | 1 mg/mL total (0.5/0.5) | Wide dermal, sensitive pts |
Advanced Strength (10 mg + 10 mg = 20 mg)
| Option | Diluent | Concentration | Use |
|---|---|---|---|
| A — High | 2 mL BS | 10 mg/mL total (5/5) | Experienced injectors, large athletes |
| B — Moderate | 5 mL BS | 4 mg/mL total (2/2) | Standard clinical |
| C — Conservative | 10 mL BS | 2 mg/mL total (1/1) | Older/comorbid, multi-site |
Frequency: 1×/wk or q5–7 days × 4–6 weeks. Athletes: 2×/wk lower dose
Maintenance: q2–4 weeks as needed
6. Route Selection & Injection Strategies
Peri-tendinous/Peri-ligamentous: Fan/ring around injured structure (avoid intra-tendinous)
IM: Deep muscle injuries, lower volume
Mesotherapy: Dermal grids for scars, aesthetic, superficial soft-tissue
Example Injection Patterns
A. Peri-Tendinous (Achilles, patellar, lateral epicondyle)
2–4 mg/mL, 0.1–0.3 mL/site, 3–6 sites, 1–4 mg/session, q7d × 4–6 wk
B. Peri-Ligamentous (MCL, LCL, ATFL)
0.1–0.2 mL/site linear/fan, 1–3 mg/session, q5–7d × 3–4 wk
C. Mesotherapy/Scar Field
1–2 mg/mL, 1–3 mm depth, 1–1.5 cm grid, 0.5–2 mg/session, weekly × 3–6
D. SC Microdosing (Systemic)
0.25–0.5 mg SC, daily–3×/wk × 2–4 wk. Multi-site overuse, heavy training.
Peptide Protocol Portal does not recommend intra-articular injection of BPC-157 or TB-500.
7. Oral Integration — RECOVER™
Why pair: GI protection (NSAID users), systemic angiogenic/endothelial support parallel to injections, GHK-Cu reinforces dermal/ECM remodeling
Moderate injury: RECOVER™ + Wolverine q7d × 4–6 wk
High-output: RECOVER™ + Wolverine weekly + optional REVIVE™ (mito) / REBALANCE™ (sleep/ANS)
8. Clinical Decision Trees
Tree 1 — Is Wolverine Blend Appropriate?
Structural soft-tissue lesion? → YES → continue
Failed conservative care? → YES → injectable Wolverine
No failure yet? → RECOVER™ ± topical first
Rapid recovery needed (athlete/occupation)? → Wolverine + RECOVER™ + PT/PRP
Contraindications? → Avoid/modify/refer
Tree 2 — Route & Dose
Localization: Focal tendon/ligament → Peri-tendinous • Diffuse muscle/fascia → SC/IM + meso • Dermal/scar → Mesotherapy • Systemic/multi-site → SC micro + RECOVER™
Severity: Mild → RECOVER™ ± low-dose SC • Moderate → RECOVER™ + targeted 1–3 mg • Severe → RECOVER™ + 3–6 mg + PRP/shockwave/PT
Patient: Older/comorbid → lower conc, slower titration • High-output athlete → more aggressive, close monitoring
Flowchart — Musculoskeletal Protocol Builder
Tendon: Acute <3 mo → RECOVER™ + Wolverine q7d × 3–4. Chronic >3 mo → q7d × 4–6 + PT + PRP
Ligament: Grade I–II → RECOVER™ + brace + Wolverine q7d × 3–4. Grade III → surgical eval ± peri-op support
Muscle/Fascia: Partial → RECOVER™ + SC/IM Wolverine ± mesotherapy. Large tear → imaging + surgical consult, Wolverine adjunct only
9. Clinical Archetypes
A — Chronic Tendinopathy (Lateral Epicondylitis)
RECOVER™ 1 cap AM 5/2 × 12 wk + Wolverine Standard 2 mg/session (0.2 mL × 5 sites), q7–10d × 4–6. Adjunctive: eccentric training, bracing, shockwave/PRP.
B — Acute Grade II MCL Sprain (Athletic)
RECOVER™ × 8–12 wk + Wolverine 3–4 mg/session, fan along MCL, 6–8 sites, q7d × 3–4. Hinged brace, PT, return-to-play testing.
C — Post-Op Soft-Tissue Repair (Rotator Cuff)
RECOVER™ once oral tolerated × 12 wk + Wolverine 2–3 mg around tendon footprint, q7–14d × 3–4 (surgeon-approved). PT, PRP, biologics.
D — Aesthetic Multi-Modality (Face/Neck)
RECOVER™ × 8–12 wk + Wolverine meso 0.5–1.5 mg intradermal grid, q2–4 wk × 3–4. GHK-Cu topical, PRiVIVE™, RF/microneedling/laser.
E — High-Output Athlete, Multi-Site Overuse
RECOVER™ + optional REVIVE™/REBALANCE™ + SC micro 0.5–1 mg q48h × 2–4 wk + targeted peri-tendinous 2–3 mg weekly. Load management, nutrition, sleep.
10. Safety & Contraindications
Absolute
- Pregnancy / Lactation
- Known hypersensitivity
- Inability to provide informed consent
Relative
- Active malignancy (angiogenesis-modulating)
- Severe hepatic disease / organ failure
- Coagulation disorders / potent anticoagulants (injectables)
- Active infection at/near injection site
- Pediatric (insufficient data)
Monitoring
Subjective: Pain scores, functional scales, recovery time, GI tolerance. Objective: Ultrasound/MRI follow-up, ROM/strength, CRP/ESR, LFTs in high-risk.
Adverse Effects
Typically mild: injection-site erythema/discomfort, transient fatigue/headache, local edema if dose/volume excessive.
Legal Disclaimer
This document is provided solely for educational and informational purposes. BPC-157, TB-500, and Wolverine Blend are not FDA-approved drugs. Peptide Protocol Portal makes no representations or warranties. By using this document, the reader agrees that Peptide Protocol Portal shall not be held liable. Use at your own risk.
References — Wolverine Blend
Provider Access Required
Create a provider account to read the full clinical guide for Wolverine Blend (BPC-157 + TB-500).